Latest filing published 20 Feb 2024 for Iovance Biotherapeutics, INC., €42.5M.
Filing timeline
BuySaleInsider track record
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Wayne P. Rothbaum: trading record in brief
Wayne P. Rothbaum (board member) discloses dealings in Iovance Biotherapeutics, Inc. to SEC (Form 4). We count 7 filings; the first trade dates from 4 December 2018 and the latest from 20 February 2024.
On the market, this insider has only ever bought: 7 purchases, €146.2M in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. 2024 to date brings 1 purchase and no sales.
The median purchase comes to €8.4M. Of 7 purchases, 4 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster.
On 20 February 2024 came the latest disclosure, an open-market purchase for €42.5M in Iovance Biotherapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Wayne P. Rothbaum
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,000,000 shares@ US$9.1532.1% of flowCommon StockSEC:0001104659-24-025520:0Canonical exit: 20 May 2024 (T+90)
- 5,000,000 shares@ US$5.3018.8% of flowCommon StockSEC:0001104659-23-101299:0Canonical exit: 14 Dec 2023 (T+90)
- 10,000,000 shares@ US$6.5046.7% of flowCommon StockSEC:0001104659-22-124196:0Canonical exit: 2 Mar 2023 (T+90)
- 500,000 shares@ US$6.76912.4% of flowCommon StockSEC:0001104659-22-067757:0Canonical exit: 29 Aug 2022 (T+90)
4 of 4 declarations
